MBFW
TSHA icon

Morton Brown Family Wealth’s Taysha Gene Therapies TSHA Stock Holding History

Morton Brown Family Wealth’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-260
Closed -$850 – 306
2025
Q3 		$850 Hold
260
– – ﹤0.01% 249
2025
Q2 		$601 Hold
260
– – ﹤0.01% 293
2025
Q1 		$361 Hold
260
– – ﹤0.01% 301
2024
Q4 		$450 Hold
260
– – ﹤0.01% 263
2024
Q3 		$523 Hold
260
– – ﹤0.01% 250
2024
Q2 		$588 Hold
260
– – ﹤0.01% 207
2024
Q1 		$746 Hold
260
– – ﹤0.01% 201
2023
Q4 		$460 Buy
+260
New +$518 ﹤0.01% 270

Other funds holding TSHA

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morton Brown Family Wealth's TSHA Position: Q4 2025 in Review

Morton Brown Family Wealth sold out of Taysha Gene Therapies (TSHA) in Q4 2025, closing a stake of 260 shares — an estimated $850 sold.

Morton Brown Family Wealth first reported a position in TSHA in Q4 2023 and held it in 8 quarters. The position peaked at $850 in Q3 2025. 195 funds tracked by Wall St. Rank hold TSHA as of Q4 2025.

  • Morton Brown Family Wealth reported no remaining Taysha Gene Therapies position as of Q4 2025 after selling out during the quarter.
  • Morton Brown Family Wealth sold 260 Taysha Gene Therapies shares in Q4 2025, an estimated $850.
  • Morton Brown Family Wealth first reported a position in Taysha Gene Therapies in Q4 2023 and held it in 8 quarters.
  • Morton Brown Family Wealth's Taysha Gene Therapies position peaked at $850 in Q3 2025.
  • 195 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q4 2025.

Based on Morton Brown Family Wealth's 13F filing for Q4 2025, filed 28 Jan 2026.